1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Colectomy incidence rates in five-year data from the observational postmarketing ulcerative colitis study of originator infliximab
- Contribution to journal › Article
- 2019
-
Mark
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
- Contribution to journal › Article
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
- Contribution to journal › Article
- 2012
-
Mark
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study
- Contribution to journal › Article
-
Mark
High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis
- Contribution to journal › Scientific review
-
Mark
Kawasaki disease : always straight to the heart?
- Contribution to journal › Article
- 2007
-
Mark
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials
- Contribution to journal › Article
